This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:
—The September, 1954, issue of the A. M. A. Archives of Internal Medicine includes a paper by Feldman and others on the controversial subject of Dicumarol [bishydroxycoumarin] therapy in moycardial infarction. May I take the liberty of pointing out an error of omission in the text which I believe results in an "editorialized" presentation of the data.The concluding summary of the paper very properly quotes the number of thromboembolic complications in the control versus the treated group but makes no references to the mortality figures in each group. Likewise, the text quotes a total mortality of 15.6% but gives no figure for the mortality in the control versus treated groups other than to state that "There was no significant difference in the mortality rate." However, on examination of the detailed tables, which are broken down in several ways, one discovers that the mortality in the treated
Weiner M. BISHYDROXYCOUMARIN (DICUMAROL) THERAPY IN MYOCARDIAL INFARCTION. AMA Arch Intern Med. 1955;95(2):354. doi:10.1001/archinte.1955.00250080176019
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: